Episode Details

This episode is brought to you by Semafor Healthcare.

Delivered weekly from David Lim, Semafor Healthcare connects the dots between decisions in government, business, and technology to reveal how they impact the future of healthcare. Each edition will provide the analysis you need to understand and stay ahead of a rapidly changing landscape. Subscribe for free.

While COVID-19 shallowed many headlines in the health care space, a lot of movement was made in various health policy areas, including prescription drug pricing.

On today's episode of Health Affairs This Week, Rachel Sachs, the Treiman Professor of Law at the Washington University in St. Louis, joins the program with Health Affairs Forefront Editor Chris Fleming to discuss Aduhelm and drug pricing.

The two discuss Rachel's latest Health Affairs Forefront article (formerly known as Health Affairs Blog) and review what happened in the prescription drug space last year and preview what to watch in 2022.

Related Links:

• Prescription Drug Policy: The Year In Review, And The Year Ahead (Health Affairs Forefront)
• The FDA's Approval Of Aduhelm: Potential Implications Across A Wide Range Of Health Policy Issues And Stakeholders (Health Affairs Forefront)
• Podcast: Drug Pricing On The Agenda For Massive Infrastructure Bill (Health Affairs This Week)

Subscribe: RSS | Apple Podcasts | Spotify | Castro | Stitcher | Deezer | Overcast

Subscribe to Semafor Healthcare for free.